newsfilter
← Latest News
GlobeNewswire·

PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month

  • PRISM MarketView published a Lung Cancer Awareness Month feature on seven small-cap companies developing lung cancer therapies & diagnostics.
  • The report follows an FDA rejection of a PD-1xVEGF bispecific antibody in EGFR-mutated lung cancer due to lack of statistically significant survival benefit.
  • Candel Therapeutics & MAIA Biotechnology are conducting Phase 3 trials using overall survival as their primary endpoint.
  • Cullinan Therapeutics & partner Taiho Oncology await an FDA decision on zipalertinib with a target action date of February 27, 2027.
  • Crescent Biopharma expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in Q1 2027.
  • Tango Therapeutics plans to disclose lung cancer data for vopimetostat in January 2027.
  • Personalis secured Medicare coverage for its NeXT Personal residual disease test for stage I to III non-small cell lung cancer.
  • bioAffinity Technologies is extending its CyPath Lung test to monitor survivors after treatment.
Company
PRISM MarketView
Keywords
PRISM MarketView, BioTech, NASDAQ, investing